Published online Aug 21, 2014. doi: 10.3748/wjg.v20.i31.10984
Revised: February 20, 2014
Accepted: May 28, 2014
Published online: August 21, 2014
Core tip: There are concerns to initiate treatment in elderly patients because of perceived lower sustained virological response (SVR) rates and serious adverse events. We aimed to evaluate safety and efficacy of pegylated interferon alfa-2a and ribavirin therapy in elderly patients. Patients were stratified according to age (< 60 years vs≥ 60 years). SVR rates showed an age related difference in patients with genotype 1 (23.7% vs 43.7%, P < 0.001) but not in genotype 2/3 infections (57.7% vs 64.6%, P = 0.341). Elderly hepatitis C virus patients differ in clinical characteristics and treatment outcome from younger patients and demand special attention from their practitioner.